Modified immune cells for aggressive T-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of T-cell cancer like T-ALL, T-LL, or certain T-cell lymphomas that has come back after a stem cell transplant.
- Your past stem cell donor must be able to give blood to make the new immune cells.
- You must be able to receive another stem cell transplant if this treatment works.
- Your cancer cells must have a protein called CD7 on at least 20% of them.
- You must be 75 years old or younger.
- You must have a special type of immune cell line available in case of a viral infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.
This trial tests a new type of immune cell therapy (multi-CAR T cells) designed to target and kill cancer cells that have a marker called CD7. It may help people with certain blood cancers that have not responded well to other treatments.
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
This trial studies a type of immune cell therapy (CAR-T) made from your own T-cells, designed to treat T-cell lymphoma or T-cell leukemia that has come back or didn’t respond. It may help by directing your immune system to attack the cancer, and it requires specific eligibility and safety checks.
This trial tests a treatment that uses your own immune cells (CAR-T) engineered to find and attack CD7 on T-cell lymphoma cells, followed by a stem cell transplant to rebuild your immune system. It is for people with certain types of T-cell lymphoma that have come back or not responded to standard treatments.
Hear when a new T-cell Acute Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.